| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PGLYRP1 |
| Uniprot No | O75594 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-196aa |
| 氨基酸序列 | QETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVSHTAGSSCNTPA SCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHL WNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHR DVQRTLSPGNQLYHLIQNWPHYRSP |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PGLYRP1重组蛋白的参考文献(虚拟示例，仅供格式参考)：
1. **"Structural and functional characterization of recombinant PGLYRP1 in bacterial defense"**
*Authors: Smith A, et al.*
*摘要：* 研究通过大肠杆菌表达系统成功纯化重组人PGLYRP1蛋白，证明其通过结合肽聚糖抑制革兰氏阳性菌生长，并解析了其晶体结构。
2. **"PGLYRP1 modulates inflammatory response in macrophages via TLR4 signaling"**
*Authors: Chen L, et al.*
*摘要：* 利用重组小鼠PGLYRP1蛋白实验，发现其通过抑制TLR4/NF-κB通路减轻脂多糖诱导的巨噬细胞过度炎症反应，提示其抗炎治疗潜力。
3. **"Recombinant PGLYRP1 enhances epithelial barrier function in colitis models"**
*Authors: Kim J, et al.*
*摘要：* 在肠道类器官模型中，重组PGLYRP1蛋白通过上调紧密连接蛋白表达，改善DSS诱导的肠黏膜屏障损伤，提出其在IBD治疗中的应用价值。
注：以上文献信息为模拟生成，实际研究中请通过PubMed/Web of Science检索真实文献(关键词：PGLYRP1 recombinant protein, antibacterial peptides, inflammation)。
Peptidoglycan Recognition Protein 1 (PGLYRP1), also known as Tag7. is a secreted innate immunity protein that plays a critical role in microbial sensing and host defense. It belongs to the PGRP family, which specifically recognizes peptidoglycan (PGN), a conserved structural component of bacterial cell walls. PGLYRP1 is encoded in humans on chromosome 19 and is expressed primarily in granulocytes, epithelial cells, and certain secretory tissues.
Structurally, PGLYRP1 contains a conserved PGRP domain that binds to PGN through a unique zinc-coordinated mechanism, enabling discrimination between pathogens and host cells. Unlike other PGRPs, it lacks enzymatic activity but exerts antimicrobial effects by inducing bacterial membrane rupture or synergizing with other immune proteins like lysozyme. Recombinant PGLYRP1 is produced using expression systems (e.g., E. coli or mammalian cells) to study its function and therapeutic potential.
Research highlights its dual role: it directly kills bacteria (e.g., Gram-positive pathogens) and modulates inflammatory responses. While PGLYRP1 deficiency exacerbates bacterial infections, overexpression has been linked to chronic inflammatory diseases, suggesting a balance in immune regulation. Its recombinant form is explored for treating antibiotic-resistant infections, sepsis, or inflammatory bowel disease (IBD). Paradoxically, some studies indicate context-dependent pro- or anti-inflammatory effects, necessitating further mechanistic studies.
Current challenges include optimizing recombinant protein stability and delivery. Nonetheless, PGLYRP1 remains a promising target for bridging antimicrobial and immunomodulatory therapies.
×
